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Merkel	   cell	   carcinoma	   (MCC),	   a	   primary	   cutaneous	   neoplasm,	   originates	   in	   the	  mechanoreceptor	  Merkel	  cells	  in	  the	  basal	  layer	  of	  the	  epidermis.	  	  Risk	  factors	  include	  UV	  exposure,	  advanced	  age	  and	   immunosuppression,	   suggesting	  an	   infectious	  etiology.	   	  MCC	  incidence	  in	  the	  US	  is	  rising,	  with	  approximately	  1500	  cases	  per	  year.	  	  The	  non-­‐enveloped,	  double-­‐stranded	   DNA	   Merkel	   cell	   polyomavirus	   (MCV)	   is	   responsible	   for	   approximately	  80%	  of	  MCC	  cases.	   	  The	  virus	  was	  discovered	  by	  subjecting	  MCC	  tissue	  samples	  to	  digital	  transcriptome	  subtraction,	  in	  which	  mRNA	  is	  isolated,	  the	  human	  transcripts	  subtracted	  in	  
silico	  and	  the	  remaining	  transcripts	  compared	  to	  viral	  sequences.	  	  	  	  MCV	   expresses	   differentially	   spliced	   Large	   (LT),	   Small	   (sT)	   and	   57	   kT	   tumor	  antigens	   from	   the	   T	   antigen	   early	   locus,	   similar	   to	   other	   polyomaviruses	   such	   as	   SV40.	  Both	  LT	  and	  sT	  are	  critical	  for	  transformation.	  	  LT	  is	  a	  helicase	  responsible	  for	  replication	  of	  the	  viral	  genome,	  however	  in	  integrated	  viral	  genomes	  it	  is	  either	  truncated	  or	  mutated	  to	   eliminate	   its	   replicative	   functions.	   sT	   contributes	   to	   transformation	   via	  hyperphosphorylation	   and	   inhibition	   of	   the	   cap-­‐dependent	   translation	   inhibitor	   4E-­‐BP1.	  	  The	   function	  of	  57	  kT	  remains	  unknown.	   	  Knockdown	  of	  LT	   induces	  necroptosis	  of	  MCV-­‐positive	  MCC	  cells,	  whereas	  sT	  expression	  in	  rodent	  Rat-­‐1	  cells	  is	  transformative.	  	  	  
v	  
Being	  that	  sT	   is	   the	  transformative	  agent	   in	  rodent	  cells,	   it	  would	  be	  of	   interest	   to	  develop	   a	  mouse	  model	   expressing	   sT	   in	   a	   tissue-­‐specific	  manner	   to	   determine	  whether	  tumor	   formation	   occurs.	   	   Indeed,	   several	   mouse	   models	   of	   SV40	   T	   antigen	   have	   been	  developed	   over	   the	   past	   decades,	   each	   resulting	   in	   tissue-­‐specific	   tumor	   formation.	   	  We	  developed	  a	  MCV	  sT	  transgenic	  mouse	  model,	  in	  which	  a	  lox-­‐stop-­‐lox	  sT	  is	  expressed	  via	  an	  ER-­‐inducible	   Cre	   gene	   under	   the	   control	   of	   the	   ubiquitin	   promoter.	   	   Upon	   tamoxifen-­‐induced	  MCV	  sT	  expression,	  ER-­‐Cre-­‐positive	  mice	  demonstrate	  severe	  weight	  loss,	  ruffled	  fur	   and	   a	   hunched	   posture,	   necessitating	   euthanasia.	   	   Western	   blotting	   reveals	   sT	  expression	  in	  several	  tissues,	  whereas	  TUNEL	  staining	  shows	  significant	  cell	  death.	  	  While	  we	   were	   unable	   to	   observe	   transformation,	   we	   believe	   this	   drastic	   phenotype	  demonstrates	   the	   validity	   of	   our	  MCV	   sT	   transgenic	  mouse	  model	   and	  warrants	   further	  investigation	  into	  the	  mechanism	  of	  death.	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1.0	  	  	  MERKEL	  CELL	  CARCINOMA	  
Cyril	   Toker	   first	   described	   Merkel	   cell	   carcinoma	   (MCC),	   an	   aggressive	   and	   rare	  form	  of	  skin	  cancer,	   in	  1972	  (Fig	   1)(1).	   	  This	  primary	  cutaneous	  neoplasm	  of	   the	  dermis	  forms	   sheets,	   nests	   or	   trabecular	   and	   anastomosing	   aggregates	   (2).	   	   Invasion	   of	   the	  overlying	  epidermis	  is	  rare,	  but	  entry	  into	  the	  subcutis	  does	  occur.	  	  MCC	  cells	  have	  granular	  or	   vesicular	   round,	   oval	   nuclei,	   along	  with	   syncytial-­‐appearing	   cytoplasm,	   small	   nucleoli	  and	  increased	  mitotic	  activity.	   	  There	  is	  variance	  on	  a	  case-­‐by-­‐case	  basis	  for	   intratumoral	  necrosis	   and	   inflammatory	   infiltration.	   	   	   The	   cytoplasm	   contains	   dense-­‐core,	   membrane	  bound	   structures,	   and	   the	   cells	   express	   chromogranin,	   synaptophysin	   and	   other	  neuropeptides,	   thus	   characterizing	   them	   as	   cutaneous	   neuroendocrine	   carcinomas	   (3).	  	  	  The	  perinuclear	  space	  contains	  cytokeratin	  intermediate	  filaments	  that	  form	  fibrous	  bodies	  through	  oligomerization.	   	   	   Indeed,	   cytokeratin	  20	  staining	   is	   the	  primary	  marker	  used	   to	  diagnose	  MCC	  (2).	  Histologically,	  MCCs	  develop	  as	  pure	  lesions,	  though	  occasionally	  there	  is	  involvement	  of	  ectodermal	  and	  mesodermal	  neoplasms	  (2).	  	  	  In	  2001,	  the	  incidence	  of	  MCC	  was	  4.4	  cases	  per	  million	  in	  the	  US	  (4).	  	  The	  five-­‐year	  survival	   rate	   for	   localized	   tumors	   was	   75%,	   whereas	   that	   for	   disseminated	   tumors	   was	  25%	  (5).	  	  Clearly,	  MCC	  is	  rare,	  but	  the	  high	  mortality	  rate	  is	  due	  to	  the	  aggressiveness	  of	  the	  neoplasm.	   	  Those	  most	  at	   risk	  are	   the	  elderly,	   the	   immunosuppressed	  such	  as	   transplant	  and	  AIDS	  patients,	  and	  those	  exposed	  to	  UV	  light	  (2,	  6,	  7).	  	  These	  factors	  suggest	  that	  MCC	  has	  an	  infectious	  etiology,	  i.e.	  viral	  (2).	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Figure	  1.	  Merkel	  cell	  carcinoma	  lesion.	  	  Located	  on	  the	  arm	  of	  the	  patient.	  	  Note	  the	  nodular,	  red	  and	  raised	  clinical	  appearance.	  	  Adapted	  from	  (2).	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2.0	  MERKEL	  CELL	  POLYOMAVIRUS	  
To	   identify	   the	   putative	   infectious	   virus	   for	   MCC,	  Feng	   et	   al.	   dissected	   four	   MCC	  tumor	   samples	   and	   isolated	   the	  mRNA	   (8).	   	   To	   distinguish	   viral	   from	  human	  mRNA,	   the	  investigators	   used	   digital	   transcriptome	   subtraction.	   	   In	   this	   method,	   mRNA	   is	   reverse	  transcribed	   into	   a	   cDNA	   library	   then	   subjected	   to	   deep	   sequencing	   to	   produce	   a	   sample	  library.	   	   Next,	   using	   the	   databases	  made	   available	   by	   the	   Human	   Genome	   Project,	   an	   in	  
silico	   subtraction	   of	   all	   human	   sequences	   is	   performed.	   	   The	   remaining	   candidate	  transcripts	   are	   then	   compared	   to	   viral	   sequences	   at	   low	   stringency	   to	   examine	   any	  homology.	  	  With	  this	  method,	  Feng	  et	  al.	  identified	  a	  transcript	  possessing	  54%	  homology	  to	   the	   tumor	  antigen	  of	   the	  African	   lymphotropic	  green	  monkey	  polyomavirus.	   	  The	  viral	  genome	  was	  then	  sequenced	  and	  dubbed	  Merkel	  cell	  polyomavirus	  (MCV),	  a	  nonenveloped	  double-­‐stranded	  DNA	  virus	  (Fig	  2).	  
Figure	  2.	  Merkel	  cell	  polyomavirus	  particles.	  Whole	  genome	  transfected	  into	  293	  cells	  for	  production.	  	  Adapted	  from	  (20).	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2.1	  PREVALENCE	  OF	  MCV	  
In	   a	   later	   study,	   8	   of	   10	  MCC	   tumors	   tested	   positive	   for	   the	   presence	   of	   the	  MCV	  genome,	  with	   some	   cells	   having	   up	   to	   48	   copies	   of	   the	   virus	   (9).	   	   Another	   27	   published	  studies	   of	   819	   MCC	   patients	   from	   North	   America,	   Europe	   and	   Asia	   in	   2010	   found	   634	  (77.4%)	  of	  tumors	  to	  be	  MCV	  positive	  (2).	  	  Both	  primary	  tumors	  and	  metastases	  displayed	  clonal	   integration	   of	   the	   viral	   genome	   (9,	   10).	   	   In	   different	   MCCs,	   the	   viral	   genome	  integrates	   at	   insertion	   sites	   throughout	   the	   host	   genome	   as	   head-­‐to-­‐tail	   concatemers,	  suggesting	   that	   tumors	  harboring	  MCV	  are	  accidental	   in	  origin	   (9,	  10-­‐13).	   	   	   Interestingly,	  several	   tissues	   from	   healthy	   and	   non-­‐MCC	   patients	   have	   low	   copy	   numbers	   of	   the	  MCV	  genome,	  indicating	  that	  MCV	  is	  a	  normal	  component	  of	  skin	  flora	  at	  different	  body	  sites	  (2,	  8,	  9,	  14).	  	  Using	  serology	  with	  antibodies	  against	  the	  viral	  structural	  protein	  VP1,	  one	  study	  found	   that	   59%	   of	   control	   subjects	   from	   the	   general	   population	   harbored	   MCV	   (15).	  Another	   study	   discovered	   that	   seroprevalence	   increases	   with	   age,	   with	   80%	   of	   North	  American	  blood	  donors	  at	  age	  50	  showing	  evidence	  for	  MCV	  exposure	  (16).	  
2.2	  MCV	  GENOME	  STRUCTURE	  
The	  viral	   genome	  of	  MCV	   is	   5,387	  bp	  with	   a	  noncoding-­‐regulatory	   region	   (NCRR)	  dividing	  an	  early	  and	  late	  coding	  region	  (Fig	  3)(2,	  8).	   	  The	  NCRR	  contains	  the	  71-­‐bp	  viral	  origin.	   	   The	   origin	   contains	   an	   AT-­‐rich	   sequence	   that	   aids	   in	   DNA	  melting,	   as	   well	   as	   8	  copies	  of	  a	  GAGGC	  pentanucleotide	  sequence.	  	  The	  NCRR	  regulates	  early	  and	  late	  viral	  gene	  expression	   using	   regulatory	   sequences	   and	   bidirectional	   transcriptional	   promoters.	   	   The	  MCV	  early	  region	  contains	  the	  tumor	  (T)	  antigen	  locus.	   	  From	  this	  locus,	   large	  (LT),	  small	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(sT)	   and	   57-­‐kT	   tumor	   antigens	   are	   expressed	   via	   differential	   splicing.	   	   The	   late	   region	  encodes	  the	  structural	  capsid	  proteins	  VP1,	  VP2	  and	  VP3	  expressed	  after	  viral	  replication.	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Figure	   3.	   	   MCV	   genome	   structure.	   	   The	   genome	   is	   5,387	   bp	   long.	   The	   noncoding	  regulatory	   region	   (NCRR)	   contains	   early	   and	   late	   promoters	   from	   which	   bidirectional	  transcription	   occurs.	   	   The	   red	   band	   in	   the	   NCRR	   indicates	   the	   viral	   origin,	   a	   71	   bp	  contiguous	   sequence	   bound	   by	   the	   large	   tumor	   antigen	   (LT).	   	   The	   T	   antigen	   locus	  comprises	   the	   early	   region,	   whereas	   the	   VP1,	   VP2	   and	   VP3	   proteins	   reside	   in	   the	   late	  region.	  	  Adapted	  from	  (2).	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2.3	  MCV	  TUMOR	  ANTIGENS	  
MCV	   LT	   contains	   several	   domains	   including	   a	   conserved	   region	   1	   (CR1),	   DnaJ,	   a	  nuclear	  localization	  signal	  (RKRK),	  Rb-­‐binding	  (LXCXE),	  origin	  binding	  domain	  (OBD),	  Zinc	  finger	  C2H2,	  Leucine	  zipper,	  ATPase	  domain	  and	  helicase	  domain	  (Fig	  4).	  	  MCV	  sT	  contains	  CR1,	  DnaJ	  and	  a	  PP2A	  binding	  site	  included	  by	  differential	  splicing	  (Fig	  4).	  	  57-­‐kT	  contains	  CR1,	  DnaJ	  and	  the	  Rb-­‐binding	  domain	  (Fig	  4).	  	  As	  indicated	  by	  its	  domain	  architecture,	  LT	  is	  involved	  in	  viral	  replication.	  	  Interestingly,	  in	  MCC	  cells	  the	  region	  of	  the	  T	  antigen	  gene	  encoding	  MCV	  LT	  has	  missense	  mutations	  or	  deletions	  that	  eliminate	  the	  replication	  motifs	  at	   the	  C-­‐terminus,	   such	  as	   the	  OBD	  or	  helicase	  domain,	   thus	  viral	  DNA	  replication	   is	   lost	  (17).	   	  Other	  mutations	  occur	  in	  the	  viral	  origin	  or	  VP1	  capsid	  protein	  (18,19).	   	   	  However,	  the	  mutations	  do	  not	   interfere	  with	  N-­‐terminal	   domains,	   such	   as	   the	  Rb-­‐binding	  domain	  nor	  sT	  domains.	  	  Accordingly,	  MCV	  LT	  from	  different	  MCC	  tumors	  varies	  in	  size	  depending	  on	  the	  site	  of	  mutation	  (9).	  	  	  It	   is	  speculated	   that	   the	  active	  viral	   replication	  results	   in	   lysis	  and	  cell	  death,	   thus	  providing	   strong	   tumor	   selection	   of	   the	   above	  MCV	  LT	  mutations	   (13).	   	   DNA	   replication	  induced	   by	   full-­‐length	   MCV	   LT	   at	   newly	   integrated	   sites	   results	   in	   replication-­‐fork	  collisions	   and	   breakage	   of	   the	   DNA	   (17).	   	   The	   reason	   for	   the	   rarity	   of	   MCC	   despite	   the	  prevalence	   of	  MCV	   infection	  may	  be	   due	   to	   integration	   of	   the	   viral	   genome	   and	  MCV	  LT	  mutation	  being	   independent	   events,	  making	   the	   combination	   less	  probable.	   Functionally,	  tumor-­‐derived	  MCV	  LT	   is	  unable	   to	   induce	   transformation	   in	   soft	   agar	   colony	   formation,	  focus	  formation	  nor	  cell	  growth	  in	  low	  serum	  (21).	  	  This	  is	  in	  contrast	  to	  the	  ability	  of	  MCV	  sT	   to	   fully	   transform	   rodent	   fibroblasts	   that	   is	   unenhanced	   by	   expression	   of	   MCV	   LT.	  	  However,	  MCV	  LT	  is	  necessary	  for	  the	  survival	  of	  MCC-­‐derived	  cell	  lines,	  and	  this	  depends	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on	  a	   functional	  Rb-­‐binding	  domain,	   the	  mutation	  of	  which	  abolishes	  Rb	  binding	   (17,	  22).	  Moreover,	  knockdown	  of	  MCV	  LT	  results	   in	  nonapoptotic	  cell	  death	  of	  MCV	  positive	  MCC	  cells	  (12).	  	  MCV	  LT	  knockdown	  in	  MCC	  cells	  was	  also	  found	  to	  decrease	  mRNA	  and	  protein	  levels	  of	  the	  anti-­‐apoptotic	  gene	  survivin,	  which	  is	  highly	  upregulated	  in	  MCV-­‐positive	  MCC	  (23).	   	   Additionally,	   ectopic	   expression	  of	  MCV	  LT	   in	   non-­‐MCC	  BJ	   primary	   cells	   increased	  survivin	  expression.	  	  An	  intact	  Rb-­‐binding	  domain	  was	  required	  for	  this	  induction.	  Finally,	  YM155,	   a	   small	   molecule	   inhibitor	   of	   survivin,	   inhibits	   MCV-­‐positive	   MCC	   growth	   (20).	  Collectively,	   these	   results	   point	   to	   a	   possible	   molecular	   mechanism	   by	   which	   MCV	   LT	  contributes	  to	  tumorigenesis	  via	  survivin.	  	  	  Whereas	  the	  function	  of	  57	  kT	  remains	  unknown,	  sT	  is	  able	  to	  fully	  transform	  Rat-­‐1	  rodent	  fibroblasts	  (21).	   	  Knockdown	  of	  sT	  in	  MCV-­‐positive	  MCC	  cells	  arrests	  proliferation	  but	   does	   not	   result	   in	   cell	   death,	   as	   knockdown	   of	  MCV	   LT	   does.	   	  Mutation	   of	   the	   PP2A	  binding	   site	   in	   sT	   does	   not	   abolish	   its	   oncogenic	   activity,	   suggesting	   that	   this	   activity	   is	  independent	  of	   sT	  binding	   to	   the	   cellular	  phosphatase	  PP2A.	   	   sT	  does,	   however,	   activate	  cap-­‐dependent	   translation	  by	  promoting	  hyperphosphorylation	  of	  4E-­‐BP1,	  a	   target	  of	   the	  Akt-­‐mTOR	   pathway,	   through	   an	   unknown	   mechanism.	   	   Phosphorylation	   of	   4E-­‐BP1	   by	  mTOR	   releases	   eIF4E,	   a	   translation	   initiation	   factor.	   	   eIF4E	   is	   then	   able	   to	   bind	   7-­‐methylguanosine-­‐capped	   mRNA	   for	   ribosomal	   assembly.	   	   Thus,	   MCV	   sT-­‐induced	  hyperphosphorylation	   of	   4E-­‐BP1	   likely	   deregulates	   cap-­‐dependent	   translation	   and	  enhances	   transformation.	   	   Despite	   the	   fact	   that	   LT	   does	   not	   enhance	   sT-­‐induced	  transformation	  of	  rodent	  fibroblasts,	  cooperation	  likely	  exists	  between	  	  T	  antigen	  isoforms	  as	  expression	  of	  sT	  in	  MCC	  cells	  that	  have	  a	  repressed	  T	  antigen	  locus	  does	  not	  rescue	  growth.	  	  
9	  
Figure	   4.	  MCV	   tumor	   antigens.	  Alternative	  splicing	  generates	   the	   three	   tumor	  antigens.	  Domain	  structure	  for	  each	  is	  shown	  in	  various	  colors.	  	  Mutation	  sites	  for	  two	  MCV	  strains	  (MCV350	  and	  MCV	  339)	  are	  indicated	  by	  red	  arrows	  over	  LT.	  	  Adapted	  from	  (20).	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3.0	  SV40	  T	  ANTIGEN	  TRANSGENIC	  MOUSE	  MODELS	  
Given	  that	  MCV	  sT	  is	  the	  transformative	  agent	  in	  rodent	  fibroblasts,	   it	  would	  be	  of	  significant	   interest	  to	  “scale-­‐up”	  the	  experimental	  system	  to	  a	  mouse	  model	  to	  determine	  whether	   a	   similar	   phenotype	   is	   observed,	   i.e.	   tumor	   development	   in	   a	   tissue	   specific	  manner.	   	   	  Such	  research	  would	  provide	  greater	  mechanistic	  and	  clinical	   insight	   into	  MCV	  biology	   and	   MCC	   itself.	   	   	   Several	   successful	   and	   informative	   mouse	   models	   of	   Simian	  vacuolating	  virus	  40	  (SV40)	  T	  antigen	  have	  been	  developed	  over	  the	  past	  decades,	  thus	  the	  idea	  is	  not	  without	  precedent	  (24).	  	  	  
3.1.	  SV40	  T-­‐ANTIGEN	  
For	   SV40	   to	   use	   the	   cellular	   machinery	   for	   its	   replication,	   and	   thereby	   induce	  transformation,	   the	   cells	   must	   re-­‐enter	   S	   phase	   (24).	   	   This	   enables	   the	   cells	   to	   grow	   in	  environments	   that	   are	   not	   permissive	   to	   untransformed	   cells,	   such	   as	   in	   the	   absence	   of	  serum.	   	  Transformed	  cells	   can	   form	  dense,	  multilayered	   foci,	   are	   anchorage	   independent	  and	   can	   induce	   tumors	   in	   immune-­‐compromised	  mice.	   	   	   SV40	  LT	   is	   responsible	   for	   viral	  replication,	   transcriptional	   regulation	   and	   virion	   assembly,	   and	   is	   both	   necessary	   and	  sufficient	   to	   induce	   transformation,	   as	   opposed	   to	   MCV	   LT.	   	   SV40	   sT	   contributes	   to	  transformation	  by	  binding	  PP2A.	   	  SV40	  LT	  contains	   five	  structural	  domains	  and	   interacts	  with	  multiple	  binding	  partners	  (Fig	  5).	  	  The	  most	  important	  interactions	  are	  with	  the	  pRb	  family	   of	   proteins	   via	   an	   LXCXE	   motif	   and	   p53	   via	   the	   ATPase	   domain.	   	   Binding	   and	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inactivation	   of	   pRbs	   by	   SV40	   LT	   induces	   cellular	   proliferation,	   whereas	   binding	   and	  inactivation	  of	  p53	  blocks	  the	  resulting	  apoptotic	  response.	  	  	  
3.2	  BRAIN	  
The	  most	   studied	  mouse	  model	   of	   SV40	   T	   antigen-­‐induced	   transformation	   in	   the	  brain	   is	   in	   the	   choroid	   plexus	   epithelium	   (CPE)	   (24).	   	   This	   tissue	   produces	   and	   filters	  cerebrospinal	   fluid	   to	   protect	   the	   brain	   from	   immune	   cells,	  metabolic	  waste	   and	   foreign	  substances.	   	   Expression	   of	   SV40	   T	   antigen	   in	   the	   CPE	   rapidly	   induces	   tumor	   formation	  independent	  of	  sT.	   	  The	  mice	  eventually	  die	  around	  1	  month	  of	  age	  (25,	  26).	   	  Blockage	  of	  the	  pRb	  pathway	  is	  essential	   for	  transformation.	   	  Normally,	  the	  re-­‐entry	  into	  S	  phase	  and	  E2F1	   upregulation	   triggered	   by	   pRb	   disruption	  would	   lead	   to	   a	   p53-­‐mediated	   apoptotic	  response,	  however	  SV40	  T	  antigen	  also	  binds	  and	   inactivates	  p53	   to	  promote	  survival	  of	  the	  rapidly	  proliferating	  cells.	  	  	  
3.3	  INTESTINE	  
SV40	   T	   antigen	   has	   been	   expressed	   in	   various	   tissues	   of	   the	   small	   intestine,	  including	   the	  endocrine	   cells	   (27-­‐29),	  Paneth	  cells	   (30),	   goblet	   cells	   (31),	   smooth	  muscle	  cells	   (32),	   and	   enterocytes	   (33-­‐35).	   	   This	   usually	   results	   in	   quiescent	   cells	   re-­‐entering	   S	  phase,	  but	   in	  some	  cases	  involution	  and/or	  apoptosis	  occurs	  (30,31).	   	  Dysplasia	  may	  also	  occur	   (33,36).	   	   Interestingly,	   a	   truncated	   amino-­‐terminal	  mutant	   of	   SV40	   T	   antigen	   that	  retains	  pRb	  binding	  but	  lacks	  p53	  binding	  is	  still	  sufficient	  to	  drive	  S	  phase	  re-­‐entry	  in	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Figure	  5.	  SV40	  Large	  T	  antigen	  structure	  and	  interactions.	  SV40	  LT	  contains	  a	  J	  domain,	  an	  LXCXE	  motif,	  an	  origin	  binding	  domain	  (OBD),	  a	  zinc-­‐finger	  domain	  (Zn-­‐D),	  an	  ATPase	  domain	  (ATPase)	  and	  a	  host	  –range	  domain	  (HR).	   	   It’s	   interaction	  with	  the	  pRbs	  and	  p53	  are	  the	  primary	  method	  by	  which	  SV40	  LT	  induces	  transformation.	  	  Adapted	  from	  (24).	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enterocytes	   and	   hyperplastic	   intestines,	   indicating	   that	   p53	   does	   not	   play	   a	   role	   (37).	  	  	  However,	   disrupting	   the	   interaction	   with	   pRb	   or	   the	   J	   domain	   abrogates	   the	   mutant	  phenotype	  (37-­‐39).	  	  Finally,	  increased	  steady	  state	  levels	  of	  the	  transcription	  factors	  E2F2	  and	  E2F3	  were	  also	  observed	  in	  enterocytes	  induced	  to	  proliferate	  by	  SV40	  T	  antigen	  (37).	  	  	  
3.4	  EYE	  
Expression	  of	  SV40	  T	  antigen	  in	  the	  retina	  of	  transgenic	  mice	  induces	  tumors	  similar	  to	  retinoblastoma	  in	  humans	  (40).	  	  In	  the	  ocular	  lens,	  T	  antigen	  induces	  tumorigenesis	  and	  decreases	   expression	   of	   differentiation	   markers,	   whereas	   a	   truncated	   amino	   terminal	  mutant	   induces	   proliferation	   and	   apoptosis,	   presumably	   due	   to	   the	   absence	   of	   the	   p53	  binding	  site,	  resulting	  in	  microphtalmia,	  microlentia	  and	  lens	  ablation	  (41).	  	  	  Disruption	  of	  pRb	  is	  necessary	  for	  induction	  of	  proliferation	  in	  the	  fiber	  cells	  of	  the	  lenses,	  but	  sT	  is	  not	  required	  (42,43).	  
3.5	  PANCREAS	  
SV40	  T	  antigen	  has	  also	  been	  expressed	  in	  the	  β-­‐cells	  in	  the	  islets	  of	  the	  pancreas	  in	  RIP-­‐Tag2	  mice	  (44).	  	  These	  cells	  re-­‐enter	  S	  phase	  and	  exhibit	  hyperplasia	  and	  dysplasia.	  	  All	  p53-­‐induced	  apoptosis	  is	  effectively	  suppressed	  in	  this	  system	  (45).	  	  Additional	  mutations,	  such	  as	  activation	  of	  the	  survival	  factor	  IGF2,	  are	  necessary	  to	  promote	  tumorigenesis	  (44,	  46).	  	  In	  acinar	  cells,	  carcinomas	  and	  metastasis	  are	  induced	  by	  expression	  of	  both	  SV40	  LT	  and	   sT	   (47-­‐50).	   	   Truncated	   amino	   terminal	   T	   antigen	   is	   also	   sufficient	   to	   generate	   this	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phenotype,	   indicating	   that	   disruption	   of	   p53	   is	   unnecessary,	   and	   sT	   is	   also	   dispensable	  (51).	  	  Finally,	  insulinomas	  and	  lymphomas	  are	  observed	  when	  T	  antigen	  is	  expressed	  in	  the	  endocrine	  cells	  of	  the	  pancreas	  (28).	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4.0	  A	  TRANSGENIC	  MOUSE	  MODEL	  OF	  MCV	  ST	  
4.1	  BACKGROUND	  AND	  SIGNIFICANCE	  
As	  previously	  mentioned,	  MCV	  sT	   is	  capable	  of	   transforming	  rodent	   fibroblasts	  on	  its	  own	  (21).	  	  This	  activity	  is	  independent	  of	  its	  PP2A	  binding	  site,	  but	  possibly	  occurs	  via	  an	   sT-­‐mediated	   increase	   in	   cap-­‐dependent	   translation	   due	   to	   hyperphosphorylation	   and	  inhibition	  of	  the	  translation	  inhibitor	  4E-­‐BP1.	  	  It	  is	  unknown,	  however,	  whether	  sT	  is	  able	  to	   transform	   cells	   in	   vivo.	   	   A	   transgenic	   mouse	   expressing	   MCV	   sT	   would	   be	   a	   more	  physiologically	   relevant	  model	   of	  MCC	   that	  would	   provide	   insight	   into	  MCV	   biology	   in	   a	  living	  host.	  	  	  
4.2	  HYPOTHESIS	  
My	  hypothesis	  is	  that	  tissue-­‐specific	  expression	  of	  MCV	  sT	  will	  induce	  tumorigenesis	  in	  a	  transgenic	  mouse	  model.	  	  MCV	  sT	  should	  be	  able	  to	  perform	  its	  oncogenic	  function	  in	  a	  living	   rodent	   similar	   to	   its	   action	   in	   rodent	   fibroblasts	   because	   both	   models	   share	  molecular	  characteristics.	  	  
4.3	  SPECIFIC	  AIM:	  GENERATE	  A	  TRANSGENIC	  MOUSE	  MODEL	  OF	  MCV	  ST	  
To	  determine	  whether	  MCV	  sT	  can	  transform	  cells	  in	  an	  in	  vivo	  context	  as	  well	  as	  in	  
vitro,	   a	   transgenic	   mouse	   model	   expressing	   sT	   in	   a	   tissue	   specific	   manner	   will	   be	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developed.	   	  The	  cre-­‐lox	  system	  is	   ideal	   for	  generating	  such	  a	  model.	   	  This	  method	  inserts	  the	  sT	  gene	  under	  the	  control	  of	  a	  constitutive	  promoter	  into	  a	  specific	  locus	  in	  the	  mouse	  genome.	  	  Between	  the	  gene	  and	  the	  promoter	  is	  a	  “stop	  cassette”	  flanked	  by	  loxP	  sites	  that	  prevents	   expression	   of	   sT	   until	   excision	   of	   the	   stop	   cassette	   by	   cre	   recombinase.	   	   Cre	   is	  expressed	  under	  the	  control	  of	  a	   tissue-­‐specific	  promoter,	  so	  excision,	  and	  sT	  expression,	  will	   only	   occur	   in	   cre-­‐expressing	   tissues.	   	   Subsequently,	   sT	   expression	   in	   the	   tissue	   of	  interest	  can	  be	  determined	  using	  western	  blotting,	  and	  tumor	  formation	  can	  be	  observed.	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5.0	  EXPERIMENTATION	  
5.1	  GENERATION	  OF	  A	  TRANSGENIC	  MCV	  ST	  KNOCK-­‐IN	  MOUSE	  
5.1.1	  Rosa26	  targeting	  and	  cre	  recombination	  
To	   study	   the	   effects	   of	   MCV	   sT	   in	   vivo,	   we	   first	   enlisted	   GenOway	   to	   develop	   a	  transgenic	  MCV	  sT	  knock-­‐in	  mouse	  for	  us.	   	  GenOway	  performed	  all	  experimental	  steps	  in	  this	   development,	   and	   then	   sent	   the	   finished	   transgenic	   heterozygous	   mice	   to	   us	   (see	  section	  5.2	  onwards	  for	  our	  experiments).	  	  The	  initial	  step	  was	  the	  selection	  of	  the	  Rosa26	  locus	  as	  the	  target	  for	  the	  sT	  transgene.	  	  This	  locus	  was	  discovered	  in	  a	  promoter	  gene	  trap	  strain,	  Rosa26-­‐β-­‐geo	  (52,53).	  	  Due	  to	  the	  ubiquitous	  expression	  of	  this	  locus	  it	  is	  often	  used	  for	  transgene	  insertion.	  	  Typically,	  a	  STOP	  cassette	  flanked	  by	  LoxP	  sites	  (floxed)	  is	  placed	  between	   the	   transgene	   and	   the	   promoter	   to	   enable	   Cre	   recombinase-­‐dependent	  expression.	   	   Another	   reason	   the	   Rosa26	   locus	   is	   desirable	   is	   because	   it	   has	   an	   open	  chromatin	   structure,	   permitting	   efficient	   homologous	   recombination	   in	   embryonic	   stem	  cells.	  	   Some	   further	   advantages	   of	   GenOway’s	   Rosa26	   knock-­‐in	   technology	   are	   1;	   a	  preselected	  integration	  site,	  2;	  analysis	  can	  be	  performed	  in	  vivo	  on	  a	  single	  transgenic	  line,	  3;	  high	  homologous	  recombination	  frequency	  is	  attainable	  at	  the	  Rosa26	  locus,	  4;	  GenOway	  has	  a	  ready-­‐to-­‐use	  targeting	  vector,	  5;	  the	  recombination	  frequency	  has	  been	  optimized	  by	  GenOway,	  and	  6;	  generation	  of	  ES	  cell	  clones	  with	  transgene	  insertion	  is	  guaranteed.	  	  Some	  disadvantages	   are	   1;	   being	   that	   the	  Rosa26	   locus	   is	   neutral,	   selection	  media	   can	   not	   be	  used,	   therefore	   an	   excisable	   neomycin	   resistance	   cassette	  must	   be	   incorporated	   into	   the	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transgene	   construct	   that	   may	   interfere	   with	   transgene	   expression,	   and	   2;	   impaired	  breeding	  in	  homozygous	  Rosa26	  knock-­‐in	  mice.	  	  
5.1.2	  Targeting	  vector	  construction	  
GenOway’s	   final	   targeting	   vector	  PAM1-­‐HR	  was	   constructed	   through	   conventional	  molecular	   biological	  methods.	   	   The	   initial	   step	  was	   insertion	   of	   a	   571	  bp	  HincII/XhoI	   sT	  fragment	   into	   the	   G194	   vector	   digested	   with	   SmaI/XhoI.	   	   This	   generates	   the	   3516	   bp	  plasmid	   PAM1-­‐CDS.	   	   Next,	   a	   585	   bp	   XhoI/SgrA1	   digested	   sT	   fragment	   is	   isolated	   from	  PAM1-­‐CDS	   and	   subcloned	   into	   the	   ARC1-­‐pA	   vector	   digested	   with	   PshA1/XmaI.	   	   The	  resulting	   15648	   bp	   plasmid	   was	   termed	   PAM1-­‐HR.	   	   Validation	   was	   performed	   through	  restriction	  analysis	  and	  partial	  sequencing	  of	  the	  coding	  exons,	  junction	  between	  selection	  cassettes	   and	   homology	   arms,	   positive	   and	   negative	   selection	   cassettes,	   and	   junctions	  between	  the	  plasmid	  backbone	  and	  homology	  arms.	  	  	  The	  sT	  transgene	  was	  placed	  under	  the	  control	  of	  the	  CAG	  promoter	  (Fig	  6).	  	  This	  is	  a	  combination	  of	  the	  CMV	  immediate	  early	  enhancer	  and	  the	  chicken	  β-­‐actin	  promoter	  that	  demonstrates	   strong	   and	   ubiquitous	   expression.	   	   The	   floxed	   STOP	   cassette	   was	   placed	  between	   the	   CAG	   promoter	   and	   sT	   transgene,	   which	   effectively	   abrogates	   transcription.	  Exxpression	  of	   the	   cre	   recombinase	   gene	  under	   the	   control	   of	   a	   tissue-­‐specific	   promoter	  leads	   to	  excision	  of	   the	  STOP	  cassette	  and	   tissue-­‐specific	   expression	  of	   the	   sT	   transgene.	  Also	  between	  the	  CAG	  promoter	  and	  STOP	  cassette	  is	  a	  neomycin	  resistance	  gene	  to	  serve	  as	  a	  positive	  selection	  marker	  that	  can	  be	  removed	  via	  cre	  expression.	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5.1.3	  Homologous	  recombination	  in	  embryonic	  stem	  cells	  
PAM1-­‐HR	   was	   linearized	   by	   digestion	   with	   AscI,	   and	   then	   subjected	   to	  phenol/chloroform	  extraction	  and	  ethanol	  precipitation	  for	   isolation	  and	  purification.	   	  40	  μg	   of	   linear	   DNA	   was	   then	   electroporated	   into	   5x106	  ES	   cells	   derived	   from	   a	   C57BL/6	  mouse	  strain	  at	  200	  V	  and	  500	  μF.	  	  After	  48	  hours	  positive	  selection	  with	  200	  μg/mL	  G418	  was	  begun,	  and	  colonies	  were	  chosen	  based	  on	  cell	  growth	  and	  morphology.	   	  After	   three	  rounds	  of	   electroporation,	   1577	   clones	  were	   isolated	   and	  amplified	  on	  duplicate	  96	  well	  plates.	  	  One	  plate	  was	  frozen	  at	  -­‐80	  °C,	  while	  the	  other	  was	  used	  for	  genomic	  DNA	  isolation	  and	  screening	  for	  homologous	  recombination	  using	  PCR	  and	  southern	  blotting.	  
5.1.4	  PCR,	  Southern	  blotting	  and	  sequencing	  to	  detect	  homologous	  recombination	  in	  
ES	  cells	  
Initially,	  PCR	  screening	  was	  used	  to	  determine	  whether	  homologous	  recombination	  had	   occurred	   at	   the	   5’	   end	   of	   ES	   cell	   genomic	   DNA.	   	   The	   reverse	   primer	   GX6044	   (5’-­‐	  GCAGTGAGAAGAGTACCACCATGAGTCC-­‐3’),	  binding	  in	  the	  short	  homology	  arm	  upstream	  of	  the	   hGHpA,	   and	   the	   forward	   primer	   GX6043	   (5’-­‐	   AAGACGAAAAGGGCAAGCATCTTCC	   -­‐3’),	  binding	   upstream	   of	   the	   targeting	   vector	   homology	   sequence,	  were	   used.	   	   The	   expected	  product	   size	   indicating	   homologous	   recombination	   is	   1870	   bp.	   	   18	   positive	   clones	  were	  isolated	  in	  the	  initial	  screening.	  	  	  For	  southern	  blotting	  to	  detect	  5’	  homologous	  recombination,	  ES	  cell	  genomic	  DNA	  was	  digested	  with	  AvrII	  and	  probed	  with	  the	  ROSA-­‐5E-­‐B	  probe	  that	  hybridizes	  upstream	  of	  the	  targeting	  vector	  homology	  sequence.	   	  The	  wild-­‐type	  locus	  will	  generate	  a	  fragment	  of	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5273	  bp,	  whereas	  with	  transgene	  insertion	  the	  fragment	  size	  will	  be	  11470	  bp.	   	  15	  out	  of	  the	  18	  PCR	  verified	  clones	  were	  found	  to	  have	  5’	  homologous	  recombination	  events.	   	  For	  southern	   blotting	   to	   detect	   3’	   homologous	   recombination,	   ES	   cell	   genomic	   DNA	   was	  digested	   with	   EcoRV	   and	   probed	   with	   the	   ROSA-­‐31-­‐W	   probe	   that	   hybridizes	   in	   the	  targeting	  vector’s	  3’	  homology	  sequence.	   	  The	  wild-­‐type	  locus	  will	  generate	  a	  fragment	  of	  9248	  bp,	  whereas	  with	  transgene	  insertion	  the	  fragment	  size	  will	  be	  13091	  bp.	  	  The	  same	  15	  clones	   identified	  using	  5’	   southern	  blotting	  were	   identified	  using	  3’	   southern	  blotting.	  	  As	  a	  final	  validation,	  the	  MCV	  sT	  transgene	  in	  these	  15	  clones	  was	  sequenced	  and	  13	  were	  found	  to	  possess	  the	  transgene.	  
5.1.5	  Chimera	  generation	  by	  blastocyst	  injection	  of	  ES	  cell	  clones	  and	  mating	  
Pregnant	  C57BL/6	  were	  used	  as	  the	  donors	  for	  blastocysts.	  	  After	  injection	  of	  the	  ES	  cell	  clones,	  blastocysts	  were	  implanted	  into	  OF1	  pseudo-­‐pregnant	  females.	   	  The	  inner	  cell	  mass	   of	   3.5	   day-­‐old	   embryos,	   the	   blastocyst	   stage,	   is	   composed	   of	   ES	   cells.	   	   Due	   to	   the	  pluripotency	   of	   ES	   cells,	   they	   are	   able	   to	   colonize	   a	   host	   blastocyst	   post-­‐injection	   and	  contribute	  to	  every	  cell	  lineage,	  including	  germline.	  	  As	  aforementioned,	  the	  ES	  cells	  in	  this	  experiment	   have	   a	   C57BL/6	   background,	   which	   generates	   black-­‐coat	   color.	   	   The	   host	  blastocysts,	  however,	  are	  from	  an	  albino	  C57BL/6J-­‐Tyrc-­‐2J/J	  strain.	  	  Therefore,	  the	  injected	  blastocysts	   are	   composed	   of	   two	   cell	   types	   from	   animals	  with	   different	   coat	   colors,	   and	  thus	   the	   patches	   of	   black	   and	   white	   fur	   on	   the	   resulting	   mice	   can	   be	   used	   to	   monitor	  chimerism.	   	   7	   males	   with	   greater	   than	   50%	   chimerism	   were	   generated	   from	   injected	  blastocysts.	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These	   male	   chimeras	   were	   mated	   to	   C57BL/6	   females	   to	   determine	   if	   the	  recombined	  ES	  cells	  contributed	  to	   the	  germ	  layer.	   	  Tail	  biopsies	  were	   taken	   from	  agouti	  generation	  F1	  pups	   for	  DNA	  isolation.	   	  PCR	  genotyping	  was	  then	  performed	  as	  described	  above	  for	  the	  recombined	  ES	  cells	  to	  determine	  if	  the	  sT	  transgene	  was	  present.	  	  Out	  of	  63	  pups	  tested,	  two	  females	  and	  one	  male	  harbored	  the	  transgene.	  	  Southern	  blot	  analysis	  as	  described	  above	  was	  also	  performed	  on	  the	  male	  and	  one	   female	  and	  confirmed	  that	   the	  pups	  were	  heterozygous	  for	  the	  transgene.	  	  	  
5.2	  BREEDING	  OF	  MCV	  ST	  TRANSGENIC	  MICE	  
5.2.1	  Generation	  of	  sT	  homozygotes	  
Upon	   receipt	   of	   the	   sT	   heterozygotes	   from	   GenOway,	   breeding	   was	   begun	   to	  generate	   sT	   homozygotes.	   	   PCR	   was	   used	   to	   distinguish	   wild-­‐type,	   heterozygote	   and	  homozygote	  offspring	  using	  genomic	  DNA	  isolated	  from	  ear	  notches.	  	  	  This	  consisted	  of	  two	  primer	   pairs,	   one	   recognizing	   the	   endogenous	   Rosa26	   locus	   (forward:	  CAATACCTTTCTGGGAGTTCTCTGC,	  reverse:	  CTGCATAAAACCCCAGATGACTACC,	  product	  of	  300	   bp)	   and	   another	   recognizing	   the	   knock-­‐in	   locus	   (forward:	   ACCGCCCCACACTTATTG,	  reverse:	   GCTTCACTTGCATCTCTTCTG,	   product	   of	   2,100	   bp).	   	   	   Out	   of	   two	   litters,	   six	   sT	  homozygotes	  were	  obtained.	  	  
5.2.2	  Breeding	  of	  sT	  homozygotes	  to	  UBC-­‐ER-­‐Cre	  heterozygotes	  
Once	   sT	   homozygotes	   were	   obtained,	   they	   were	   bred	   to	   B6.Cg-­‐Tg(UBC-­‐cre/ERT2)1Ejb/J	   heterozygotes	   (Jackson	   Labs	   #008085).	   	   These	   mice	   express	   the	   cre	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recombinase	   fused	   to	   the	   estrogen	   receptor	   and	   under	   the	   control	   of	   the	   ubiquitin	  promoter,	  which	  is	  expressed	  in	  all	   tissues.	   	  Upon	  introduction	  of	  an	  estrogen	  analog,	  the	  ER-­‐cre	  translocates	  into	  the	  nucleus	  to	  catalyze	  recombination	  of	  loxP	  sites.	   	  This	  enables	  excision	  of	  the	  STOP	  cassette	  located	  between	  the	  sT	  transgene	  and	  CAG	  promoter,	  thereby	  inducing	   sT	   expression	   in	   all	   tissues	   (Fig	   6).	   	   PCR	   using	   primers	   specific	   to	   the	   cre	  transgene	  (forward:	  GCG	  GTC	  TGG	  CAG	  TAA	  AAA	  CTA	  TC	  and	  reverse:	  GTG	  AAA	  CAG	  CAT	  TGC	  TGT	  CAC	  TT,	  product	  of	  100	  bp)	  was	  used	  to	  identify	  offspring	  carrying	  the	  UBC-­‐ER-­‐cre	  transgene.	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5.3	  TAMOXIFEN	  INJECTIONS	  
Tamoxifen,	   an	   estrogen	   analog	   converted	   to	   4-­‐hydroxytamoxifen	   in	   the	   liver,	  was	  purchased	   from	   Sigma.	   	   It	   was	   dissolved	   in	   corn	   oil	   (Sigma)	   at	   65°C	   for	   1	   hour,	   filter	  sterilized,	   and	   injected	   intraperitoneally	   into	   4	   week	   old	   genotyped	   mice	   from	   crosses	  between	  sT	  homozygous	  females	  and	  UBC-­‐ER-­‐cre	  heterozygous	  males.	  	  A	  total	  of	  11	  mice,	  six	  UBC-­‐ER-­‐cre	  negative	  and	  5	  UBC-­‐ER-­‐cre	  positive	  from	  two	  separate	  litters,	  were	  injected	  once	  at	  0.2	  mg/g	  body	  weight	  each	  day	  for	  three	  days.	  One	  UBC-­‐ER-­‐cre	  positive	  mouse	  was	  not	  injected	  with	  tamoxifen	  as	  a	  negative	  control.	  	  Injected	  mice	  were	  weighed	  on	  days	  zero	  and	  three	  (Fig	  7).	  	  Any	  mouse	  having	  a	  20%	  loss	  in	  body	  weight	  was	  sacrificed	  by	  carbon	  dioxide	  asphyxiation	  followed	  by	  cervical	  dislocation.	  	  We	  then	  harvested	  the	  brain,	  heart,	  intestines,	  kidneys,	  liver,	  lungs,	  spleen	  and	  muscle.	  	  Pieces	  of	  each	  organ	  were	  either	  flash	  frozen	  on	  dry	  ice	  and	  stored	  at	  -­‐80°C	  for	  western	  blots	  or	  fixed	  in	  10%	  buffered	  formalin	  for	  slide	  preparation.	  	  	  	  
5.4	  WESTERN	  BLOTS	  OF	  TISSUE	  SURVEY	  FOR	  ST	  EXPRESSION	  
Organ	  samples	  stored	  at	  -­‐80°C	  were	  thawed	  and	  lysis	  buffer	  (50	  mM	  Tris-­‐HCl,	  150	  mM	  NaCl,	  1%	  Triton	  X-­‐100,	  with	  Roche	  Complete	  Mini	  protease	  inhibitors)	  added.	  	  Samples	  were	   pulverized	   with	   a	   pestle,	   sonicated,	   centrifuged	   at	   10	   krpm	   and	   lysate	   collected.	  Protein	   concentration	   was	   measured	   using	   the	   Biorad	   DC	   protein	   assay	   kit	   with	   BSA	  standards	  and	  a	  Biotek	  Synergy	  2	  plate	  reader.	  	  For	  western	  blots	  to	  detect	  sT	  expression	  in	  the	  various	  tissues	  for	  each	  mouse,	  50	  μg	  protein	  was	  loaded	  onto	  a	  12%	  polyacrylamide	  gel	  and	  run	  at	  15	  mA	  until	  the	  dye	  front	  reached	  the	  bottom	  of	  the	  gel.	  	  Protein	  was	  then	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Mouse	  Weight	  vs.	  Day	  
20.1.1	  F	  20.1.2	  F	  20.1.3	  F	  20.1.4	  F	  20.1.1	  M	  20.1.2	  M	  20.1.3	  M	  20.1.4	  M	  22.1.1F	  22.1.2	  F	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transferred	   to	  a	  nitrocellulose	  membrane	  at	  80	  V	   for	  2	  hours.	   	  Membranes	  were	  blocked	  using	  5%	  dry	  milk	   in	  TBS	  at	   room	   temperature	   for	  1	  hour,	  washed	  with	  TBST,	   and	   then	  probed	   overnight	   at	   4°C	   with	   the	   CM8E6	   (1:500	   in	   5%	  milk	   in	   TBS)	   in-­‐house	   antibody	  against	  MCV	  sT	  and	  the	  Sigma	  clone	  B-­‐5-­‐2-­‐2	  monoclonal	  mouse	  antibody	  against	  α-­‐tubulin	  (1:10,000	  in	  5%	  milk	  in	  TBS)	  as	  a	  loading	  control.	  Membranes	  were	  washed	  with	  TBST	  and	  Licor	  800	  infrared	  dye-­‐conjugated	  anti-­‐mouse	  secondary	  antibody	  (1:10,000	  in	  5%	  milk	  in	  TBS)	  was	  then	  added	  for	  one	  hour	  at	  room	  temperature	  in	  the	  dark	  for	  visualization	  using	  a	  Licor	   Odyssey	   imager	   (Figs	   8-­‐10).	   	   MCV	   sT	   was	   observed	   in	   various	   tissues	   in	   mice	  harboring	   the	  UBC-­‐ER-­‐cre	   transgene	   and	   injected	  with	   tamoxifen,	   but	   not	   in	  UBC-­‐ER-­‐cre	  negative	   mice	   injected	   with	   tamoxifen	   nor	   UBC-­‐ER-­‐cre	   positive	   mice	   not	   injected	   with	  tamoxifen.	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Figure	  8.	  MCV	  sT	  and	  α-­‐tubulin	  expression	  in	  various	  mice.	  MCV	  sT	  expression,	  at	  17	  kD,	   is	   only	   observed	   in	  mouse	   20.1.1	  M	   that	   harbors	   UBC-­‐ER-­‐cre	   and	  was	   injected	  with	  tamoxifen.	  	  	  
α-Tubulin 
(50 kD) 
      sT 
(17 kD) 
UBC-Cre +/- sT +/-, + tamoxifen (20.1.1 M) UBC-Cre -/- sT +/-, + tamoxifen (20.1.4 M) 

















































































      sT 
(17 kD) 
sT tissue survey in UBC-Cre + and - mice 
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5.5	  TUNEL	  STAINING	  TO	  DETECT	  CELL	  DEATH	  IN	  TISSUE	  SAMPLES	  
Organ	  samples	   in	  10%	  buffered	  formalin	   from	  a	  UBC-­‐ER-­‐cre	  positive	  mouse	  and	  a	  UBC-­‐ER-­‐cre	  negative	  mouse	  were	  sent	  to	  Research	  Histology	  Services	  at	  the	  University	  of	  Pittsburgh	  for	  paraffin	  embedding	  and	  slide	  preparation,	  TUNEL	  (terminal	  dUTP	  nick-­‐end	  labeling)	   and	   hematoxylin/eosin	   staining.	   	   Increased	   cell	   death	   was	   observed	   in	   the	  intestine,	  lung,	  liver	  and	  spleen	  (Figs	  11-­‐14).	  	  
5.6	  DISCUSSION	  
The	  purpose	  of	  the	  above	  experiments	  was	  to	  study	  the	  effects	  	  MCV	   sT	   in	   vivo.	   To	  do	  this,	  we	  crossed	  a	  transgenic	  MCV	  sT	  knock-­‐in	  mouse	  developed	  by	  GenOway	  to	  UBC-­‐ER-­‐cre	  mice	  to	  derive	  progeny	  that	  express	  MCV	  sT	  in	  all	  tissues	  upon	  tamoxifen	  induction.	  Addition	   of	   tamoxifen	   resulted	   in	   dramatic	   weight	   loss,	   which	   necessitated	   eventual	  sacrifice,	   in	  offspring	  carrying	  the	  UBC-­‐ER-­‐cre	  transgene.	   	  Western	  blots	  of	  various	  tissue	  lysates	   detected	   MCV	   sT	   expression	   in	   these	   offspring.	   	   This	   indicates	   that	   tamoxifen	  addition	  successfully	  induced	  ER-­‐cre	  translation	  into	  the	  nucleus	  and	  subsequent	  excision	  of	  the	  STOP	  cassette	  that	  had	  been	  blocking	  MCV	  sT	  expression.	  	  However,	  the	  connection	  between	  MCV	  sT	  expression	  and	  the	  dramatic	  weight	  loss	  observed	  remains	  obscure.	  One	  possibility	   is	   increased	   cell	   death	   in	   response	   to	  MCV	   sT	   expression.	   	   TUNEL	  staining	   of	   UBC-­‐ER-­‐cre	   positive	  mouse	   tissue	   indicated	   significant	   cell	   death	   in	   the	   lung,	  liver,	   intestine	   and	   spleen	   compared	   to	   UBC-­‐ER-­‐cre	   negative	  mouse	   tissue.	   	   The	   drastic	  increase	   in	   viral	   oncogene	   expression	   may	   have	   severely	   deleterious	   effects	   on	   cellular	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function,	   thus	   inducing	   a	   self-­‐destructive	   cascade.	   	   Being	   that	   MCV	   sT	   is	   expressed	  systemically	   in	   UBC-­‐ER-­‐cre	   positive	   mice	   upon	   tamoxifen	   induction,	   such	   widespread	  cellular	   damage	   may	   promote	   organ	   failure,	   particularly	   in	   the	   intestines,	   which	   would	  disrupt	  nutrient	  uptake.	  	  	  This	  could	  account	  for	  the	  observed	  severe	  weight	  loss.	  	  However,	  the	  molecular	  mechanism	  by	  which	   induced	  MCV	   sT	   expression	  may	   result	   in	   cell	   death	  remains	  unknown,	  although	  possible	  experiments	  are	  proposed	  in	  section	  6.1.	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Figure	  11.	  TUNEL	  and	  H&E	  staining	  of	  intestine	  from	  a	  cre	  positive	  and	  cre	  negative	  










Figure	   12.	   TUNEL	   and	   H&E	   staining	   of	   lung	   from	   a	   cre	   positive	   and	   cre	   negative	  









Figure	   13.	   TUNEL	   and	   H&E	   staining	   of	   liver	   from	   a	   cre	   positive	   and	   cre	   negative	  









Figure	  14.	  TUNEL	  and	  H&E	   staining	  of	   spleen	   from	  a	   cre	  positive	   and	   cre	  negative	  









6.0	  FUTURE	  DIRECTIONS	  
6.1	  EXPRESSION	  OF	  MOLECULAR	  MARKERS	  IN	  RESPONSE	  TO	  ST	  
As	   mentioned	   above,	   expression	   of	   MCV	   sT	   leads	   to	   hyperphosphorylation	   and	  inhibition	   of	   the	   cap-­‐dependent	   translation	   inhibitor	   4E-­‐BP1,	   thus	   promoting	   increased	  cap-­‐dependent	   translation,	  which	  may	  be	  a	  mechanism	  of	   transformation	   (21).	   	   It	  would	  therefore	   be	   of	   interest	   to	   determine	   whether	   there	   is	   an	   increase	   of	   4E-­‐BP1	  hyperphosphorylation	  in	  tissues	  from	  UBC-­‐ER-­‐cre	  positive	  mice	  that	  express	  sT.	  This	  could	  be	  evaluated	  using	  western	  blotting	  against	  phosphorylated	  4E-­‐BP1.	  	  If	  tissues	  expressing	  sT	  display	  hyperphosphorylated	  4E-­‐BP1,	  it	  confirms	  that	  this	  mechanism	  is	  present	  in	  vivo	  as	  well	  as	  in	  an	  in	  vitro	  cell	  culture	  model,	  and	  thus	  is	  more	  relevant.	  	  	  Being	  that	  cell	  death	  was	  observed	  in	  several	  tissues	  via	  TUNEL	  staining,	  it	  may	  also	  be	   worthwhile	   to	   determine	   whether	   these	   same	   tissues	   express	   markers	   of	   apoptosis	  using	  western	  blot.	  	  These	  could	  include	  cleaved	  PARP,	  caspase-­‐3	  cleavage,	  and	  a	  variety	  of	  the	  Bcl	  proteins.	  	  This	  would	  provide	  a	  possible	  mechanism	  by	  which	  sT	  induces	  cell	  death	  in	   specific	   tissues	   where	   it	   is	   expressed.	   	   Another	   marker	   could	   be	   upregulation	   of	   the	  tumor	   suppressor	   p53,	   which	   can	   also	   lead	   to	   apoptosis	   in	   response	   to	   transforming	  agents.	  	  If	  sT	  is	  such	  an	  agent,	  then	  it	  may	  induce	  activation	  of	  p53.	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6.2	  DECREASING	  THE	  DOSAGE	  OF	  TAMOXIFEN	  
Our	   dosage	   of	   0.2	   mg/g	   of	   tamoxifen	   used	   for	   injection	   led	   to	   the	   necessary	  sacrificing	   of	   all	   UBC-­‐ER-­‐cre	   positive	   mice	   due	   to	   weight	   loss.	   	   This	   dosage	   may	   have	  induced	   such	   a	   high	   amount	   of	   sT	   expression	   that	   it	   proved	   toxic	   to	   the	  mice.	   	   The	   cell	  death	  observed	  in	  the	  intestines	  may	  have	  been	  an	  indication	  of	  this	  toxicity;	  poor	  nutrient	  uptake	  in	  the	  intestines	  may	  have	  promoted	  the	  severe	  and	  sudden	  weight	  loss	  observed	  in	  these	   mice.	   	   The	   euthanizing	   of	   these	   mice	   prevented	   us	   from	   observing	   any	   tumor	  formation	  and	  thus	  this	  was	  not	  a	  valid	  model	  of	  cancer	  development.	   	  Therefore,	  using	  a	  lower	  dose	  of	  tamoxifen	  may	  induce	  lower	  amounts	  of	  sT	  expression	  and	  thus	  circumvent	  the	   cell	   death	   and	  weight	   loss.	   	   This	  would	   enable	   the	  mice	   to	   live	   longer	   and	  provide	   a	  better	  chance	  of	  observing	  any	  possible	  tumor	  formation.	   	  A	  good	  starting	  dosage	  may	  be	  0.02	  mg/g	  of	  tamoxifen,	  ten	  times	  less	  than	  our	  initial	  dosage.	  	  If	  this	  dosage	  also	  results	  in	  the	   weight	   loss	   and	   necessary	   sacrificing	   of	   UBC-­‐ER-­‐cre	   positive	   mice	   before	   tumor	  formation	   is	  observed,	   then	   the	  dosage	  could	  again	  be	  decreased	   to	  promote	  survival.	   	  A	  drawback	  to	   this	  experiment	   is	   that	   lower	  dosages	  of	   tamoxifen	  may	  not	  promote	  robust	  expression	  of	  sT	  in	  the	  mice,	  and	  thus	  no	  possible	  tumor	  formation	  will	  be	  observed.	  	  
6.3	  USING	  CRE	  LINES	  DRIVEN	  BY	  DIFFERENT	  PROMOTERS	  
The	  ER-­‐cre	  transgene	  we	  used	  in	  this	  experiment	  was	  under	  the	  control	  of	  the	  ubiquitin	  promoter,	  resulting	  in	  the	  expression	  of	  ER-­‐cre	  in	  all	  tissues.	  	  When	  crossed	  to	  MCV	  sT	  transgenic	  mice	  and	  after	  translocation	  of	  ER-­‐cre	  into	  the	  nucleus	  using	  tamoxifen	  injection,	  sT	  is	  expressed	  in	  multiple	  tissues,	  as	  observed	  in	  our	  western	  blots.	  	  This	  
38	  
widespread	  expression	  of	  sT	  may	  be	  toxic	  to	  the	  mice,	  thus	  resulting	  in	  the	  observed	  weight	  loss,	  cell	  death	  and	  necessary	  sacrificing.	  	  Accordingly,	  using	  different	  promoters	  to	  drive	  the	  cre	  transgene	  may	  be	  worthwhile.	  	  Being	  that	  MCC	  is	  specific	  to	  Merkel	  cells	  in	  the	  skin,	  using	  the	  Atoh1	  promoter,	  which	  controls	  expression	  of	  the	  Atoh1	  transcription	  factor	  in	  Merkel	  cells	  and	  the	  CNS,	  may	  be	  worthwhile	  (54).	  	  We	  attempted	  this	  using	  a	  constitutive	  Atoh1-­‐cre	  line	  (B6.Cg-­‐Tg(Atoh1-­‐cre)1Bfri/J,	  Jackson	  Labs	  #011104)	  crossed	  to	  our	  MCV	  sT	  transgenic	  mice,	  but	  obtained	  no	  viable	  cre-­‐positive	  pups	  according	  to	  PCR	  genotyping.	  	  This	  may	  indicate	  that	  constitutive	  expression	  of	  sT	  in	  the	  CNS	  is	  toxic	  to	  embryos.	  	  Another	  constitutive	  promoter	  we	  tried	  was	  that	  for	  keratin	  14,	  a	  skin-­‐specific	  structural	  protein	  (Tg(KRT14-­‐cre)1Amc/J,	  Jackson	  Labs	  #004782)(55).	  	  However,	  this	  also	  produced	  no	  viable	  cre-­‐positive	  pups.	  	  Despite	  these	  negative	  results,	  other	  promoters	  may	  still	  be	  of	  interest,	  such	  as	  for	  other	  skin-­‐specific	  proteins.	  	  This	  would	  be	  the	  most	  relevant	  
in	  vivo	  model	  given	  that	  MCC	  is	  a	  skin	  cancer. 
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